{"gene":"ZNF451","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":2015,"finding":"The N-terminal domain of ZNF451 constitutes the catalytic module for SUMO E3 ligase activity, containing tandem SUMO-interaction motifs (SIMs) bridged by a Pro-Leu-Arg-Pro (PLRP) motif. The first SIM and PLRP motif engage thioester-charged E2~SUMO while the second SIM binds a second SUMO molecule on the back side of E2, stabilizing the closed configuration for nucleophilic attack. ZNF451 is SUMO2-specific, and SUMO modification of ZNF451 itself may contribute to activity by providing a second SUMO molecule interacting with E2.","method":"Crystal structure determination combined with biochemical assays and mutagenesis of the catalytic module","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro biochemical reconstitution plus mutagenesis in a single rigorous study","pmids":["26524494"],"is_preprint":false},{"year":2017,"finding":"ZATT (ZNF451) is a multifunctional DNA repair factor that resolves topoisomerase 2 DNA-protein cross-links (TOP2cc) via two mechanisms: (1) ZATT binding to TOP2cc facilitates proteasome-independent TDP2 hydrolase activity on stalled TOP2cc, and (2) ZATT SUMO ligase activity promotes TDP2 interactions with SUMOylated TOP2 through a 'split-SIM' SUMO2 engagement platform, enabling efficient TDP2 recruitment.","method":"Biochemical reconstitution assays, Co-IP/pulldown, in vitro TDP2 hydrolase activity assays, cell-based DNA repair assays, mutagenesis","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including in vitro reconstitution, activity assays, mutagenesis, and cellular validation in a single study","pmids":["28912134"],"is_preprint":false},{"year":2008,"finding":"ZNF451 localizes to PML bodies in the nucleus, interacts with SUMO E2 conjugase Ubc9 and SUMOs, and is itself covalently SUMOylated at multiple non-consensus sites. Its noncovalent SUMO-binding activity (SIM) is required for its own sumoylation. SUMO modification regulates ZNF451 nuclear compartmentalization: co-expression with SENP1 or SENP2 redistributes ZNF451 from nuclear domains to speckles/nucleoplasm. ZNF451 interacts with PIAS1 (which does not act as an E3 for ZNF451) resulting in disintegration of ZNF451 nuclear domains. ZNF451 interacts weakly with androgen receptor (AR) in a SUMO-1-enhanced manner. Ablation of endogenous ZNF451 in prostate cancer cells significantly decreases expression of AR target genes.","method":"Co-IP, immunofluorescence/localization, sumoylation assays, siRNA knockdown, reporter assays, SENP co-expression experiments","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple orthogonal methods (Co-IP, localization, knockdown with gene expression readout) in a single lab","pmids":["18656483"],"is_preprint":false},{"year":2016,"finding":"ZNF451 isoform 1 (ZNF451-1) functions as a SUMO2/3-specific E3 ligase for PML and selected PML body components in vitro, using the same biochemical mechanism as SUMO chain formation. In vivo, RNAi depletion of ZNF451-1 leads to PML stabilization and an increased number of PML bodies, while PML degradation upon arsenic trioxide treatment is not ZNF451-1 dependent. ZNF451-1 cooperates with RNF4 to regulate physiological PML levels.","method":"In vitro SUMO E3 ligase assays, mutational analysis, RNAi knockdown with immunofluorescence and western blot readouts","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution plus cellular KD with specific phenotypic readout, single lab","pmids":["27343429"],"is_preprint":false},{"year":2020,"finding":"Upon replication stress, TOP2A SUMOylation is mediated by the SUMO E3 ligase ZATT (ZNF451), which promotes recruitment of the SUMO-targeted DNA translocase PICH to stalled forks. Disruption of the ZATT-TOP2A-PICH axis results in accumulation of partially reversed forks and enhanced genome instability, placing ZATT in a sequential two-step fork reversal pathway downstream of HLTF/ZRANB3/SMARCAL1.","method":"Co-IP, SUMO modification assays, replication fork analysis (electron microscopy/fiber assays), genetic epistasis using knockout/knockdown cell lines, immunofluorescence","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, multiple KO/KD genetic epistasis experiments, replication fork phenotype readout with multiple orthogonal methods","pmids":["33296677"],"is_preprint":false},{"year":2021,"finding":"ZNF451 directly binds to and SUMOylates TWIST2 at lysine 129, blocking ubiquitination and proteasome-dependent degradation of TWIST2. Ectopic expression of ZNF451 increases TWIST2 protein levels in mammary epithelial cells and increases expression of mesenchymal markers, while depletion of ZNF451 suppresses mesenchymal phenotypes.","method":"Co-IP, in vitro SUMOylation assay, ubiquitination assay, site-directed mutagenesis (K129 site), overexpression/knockdown with immunoblot and EMT marker readouts","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, mutagenesis of SUMOylation site, and functional cellular assays in single lab","pmids":["33791162"],"is_preprint":false},{"year":2023,"finding":"ZNF451 interacts with the transcriptional activator SLUG and the complex preferentially recruits the acetyltransferase PCAF to the CCL5 promoter, enhancing acetylation of SLUG and local chromatin to selectively facilitate CCL5 transcription. This promotes recruitment and activation of tumor-associated macrophages.","method":"Co-IP, ChIP, luciferase reporter assays, peptide competition experiments, macrophage migration/activation assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP, ChIP, and functional cellular assays in single lab with multiple orthogonal methods","pmids":["37342906"],"is_preprint":false},{"year":2023,"finding":"ZATT (ZNF451) has a TDP2-independent role in promoting cell survival after etoposide treatment. The N-terminal 1-168 residues of ZATT are required for interaction with TOP2 and this interaction is critical for etoposide sensitivity. Depletion of ZATT accelerates TOP2 degradation after etoposide or cycloheximide treatment, suggesting ZATT promotes TOP2 stability and participates in TOP2 turnover. ZATT/TDP2 double knockout shows additive hypersensitivity to etoposide, confirming independent pathways.","method":"Genome-wide CRISPR screens, deletion mutant analysis, Co-IP, TOP2 stability assays (CHX chase), double KO epistasis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen plus deletion mutant Co-IP plus genetic epistasis (DKO), single lab","pmids":["37047518"],"is_preprint":false},{"year":2025,"finding":"ZNF451 catalyzes SUMO2 modification of RNF168 at DNA damage sites, stabilizing RNF168 and enhancing its accumulation at damage sites, which increases ubiquitination of downstream histone H2A/H2AX and promotes DSB repair. ZNF451 and RNF8 jointly regulate RNF168 in a competitive and cooperative manner: the interaction of RNF168 with either ZNF451 or RNF8 mutually inhibits each other, yet simultaneous loss of both markedly impedes RNF168 recruitment to damage sites.","method":"Co-IP, SUMOylation assays, immunofluorescence at damage sites, genetic epistasis (KO/KD of ZNF451, RNF8, RNF168), H2A/H2AX ubiquitination assays, irradiation experiments","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, in-cell SUMOylation assays, and genetic epistasis, single lab","pmids":["40055579"],"is_preprint":false},{"year":2024,"finding":"ZATT (ZNF451) inhibits TOP2B catalytic activity in response to estrogen stimulation, contributing to topological regulation of the estrogen transcriptional response. This inhibition requires estrogen receptor α (ERα), a non-catalytic function of TOP2A, and ZATT SUMO ligase activity, stabilizing regulatory chromatin contacts likely through local accumulation of DNA supercoiling.","method":"ChIP, topoisomerase activity assays, genetic epistasis (KO/KD of ZATT, TOP2A, TOP2B), 3D genome contact analysis, transcriptional assays","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 2-3 / Weak — preprint, single lab, multiple methods but not yet peer reviewed","pmids":["38328138"],"is_preprint":true},{"year":2024,"finding":"ZNF451 downregulation in pulmonary fibrosis triggers fibroblast activation by increasing expression of PDGFB and subsequently activating PI3K/Akt signaling. ZNF451 knockout mice develop more severe pulmonary fibrosis, while ZNF451 overexpression protects mice from bleomycin-induced fibrosis.","method":"ZNF451 knockout mice, lentiviral overexpression, RNA-seq, migration assays, immunofluorescence, immunoblot","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO mouse model plus overexpression rescue plus pathway identification by RNA-seq, single lab","pmids":["38600524"],"is_preprint":false}],"current_model":"ZNF451 (ZATT) is a SUMO2/3-specific E3 ligase whose N-terminal tandem-SIM/PLRP catalytic module stabilizes the E2~SUMO thioester for transfer; it SUMOylates multiple substrates—including TOP2, TOP2A (promoting fork reversal via PICH recruitment), PML, RNF168 (stabilizing it for H2A/H2AX ubiquitination in DSB repair), and TWIST2 (blocking its proteasomal degradation to drive EMT)—and directly facilitates TDP2-mediated hydrolytic resolution of trapped TOP2 cleavage complexes through a 'split-SIM' SUMO2 engagement platform, while also acting as a transcriptional co-regulator at PML bodies that modulates androgen receptor target gene expression and, in the context of estrogen signaling, inhibits TOP2B catalytic activity to shape chromatin topology."},"narrative":{"mechanistic_narrative":"ZNF451 (ZATT) is a SUMO2/3-specific E3 ligase that operates at the interface of SUMO conjugation, genome maintenance, and transcriptional control [PMID:26524494, PMID:28912134]. Its catalytic activity resides in an N-terminal module of tandem SUMO-interaction motifs bridged by a Pro-Leu-Arg-Pro (PLRP) element: the first SIM and PLRP engage thioester-charged E2~SUMO while the second SIM binds a second SUMO on the back face of the E2, stabilizing the closed conformation that drives transfer [PMID:26524494]. Through this chemistry ZNF451 modifies multiple substrates and assembles SUMO-based recognition platforms. In DNA repair, it resolves trapped topoisomerase-2 DNA-protein cross-links both by directly facilitating proteasome-independent TDP2 hydrolase activity and by SUMOylating TOP2 to create a 'split-SIM' SUMO2 platform for TDP2 recruitment [PMID:28912134]; under replication stress it SUMOylates TOP2A to recruit the translocase PICH and drive fork reversal [PMID:33296677]; and it SUMOylates RNF168 at damage sites to stabilize it and amplify downstream H2A/H2AX ubiquitination during double-strand break repair [PMID:40055579]. ZNF451 localizes to PML nuclear bodies, where it acts as a SUMO2/3 E3 for PML and cooperates with RNF4 to set physiological PML levels [PMID:18656483, PMID:27343429]. Beyond genome maintenance it stabilizes substrates such as TWIST2 by blocking its ubiquitin-dependent degradation to promote mesenchymal phenotypes [PMID:33791162] and serves as a transcriptional co-regulator, supporting androgen-receptor target gene expression and partnering with SLUG to recruit PCAF and selectively activate CCL5 [PMID:18656483, PMID:37342906]. In vivo, ZNF451 loss exacerbates bleomycin-induced pulmonary fibrosis through PDGFB/PI3K-Akt-driven fibroblast activation [PMID:38600524].","teleology":[{"year":2008,"claim":"Established ZNF451 as a SUMO-pathway protein by showing it localizes to PML bodies, binds Ubc9 and SUMO, is itself SUMOylated, and influences androgen-receptor target gene expression — the first functional placement of the protein.","evidence":"Co-IP, immunofluorescence, sumoylation and reporter assays, siRNA knockdown in prostate cancer cells","pmids":["18656483"],"confidence":"Medium","gaps":["Did not define catalytic E3 activity or mechanism","SUMO sites mapped only as non-consensus, not residue-resolved","AR co-regulation correlative, no direct enzymatic link"]},{"year":2015,"claim":"Resolved the catalytic mechanism, showing ZNF451's N-terminal tandem-SIM/PLRP module stabilizes the E2~SUMO closed configuration and confers SUMO2 specificity, defining it as a bona fide SUMO E3 ligase.","evidence":"Crystal structure with in vitro biochemistry and mutagenesis of the catalytic module","pmids":["26524494"],"confidence":"High","gaps":["Physiological substrate repertoire not addressed structurally","Contribution of ZNF451 auto-SUMOylation to activity inferred, not quantified"]},{"year":2016,"claim":"Identified PML and PML body components as cellular SUMO2/3 substrates of ZNF451 and placed it alongside RNF4 in regulating PML homeostasis.","evidence":"In vitro SUMO E3 ligase assays, mutational analysis, RNAi knockdown with IF/WB readouts","pmids":["27343429"],"confidence":"Medium","gaps":["Arsenic-induced PML degradation shown ZNF451-independent, leaving trigger specificity open","Direct vs indirect cooperation with RNF4 not mechanistically dissected"]},{"year":2017,"claim":"Defined ZATT/ZNF451 as a topoisomerase-2 cleavage-complex repair factor that both potentiates TDP2 hydrolase activity directly and builds a split-SIM SUMO2 platform to recruit TDP2 to SUMOylated TOP2.","evidence":"Biochemical reconstitution, Co-IP, in vitro TDP2 activity assays, cell-based repair assays, mutagenesis","pmids":["28912134"],"confidence":"High","gaps":["Relative in vivo weight of catalytic vs non-catalytic resolution unresolved","Substrate specificity across TOP2 isoforms not delineated"]},{"year":2020,"claim":"Extended ZATT into replication-stress responses, showing TOP2A SUMOylation recruits PICH to drive a defined step of fork reversal, linking SUMO ligase activity to genome stability at stalled forks.","evidence":"Co-IP, SUMO modification assays, replication fork EM/fiber analysis, genetic epistasis in KO/KD lines","pmids":["33296677"],"confidence":"High","gaps":["Trigger for ZATT engagement at forks not defined","Interplay with the upstream HLTF/ZRANB3/SMARCAL1 step mechanistically incomplete"]},{"year":2021,"claim":"Broadened the substrate scope beyond genome maintenance by showing ZNF451 SUMOylates TWIST2 at K129 to block its degradation and promote mesenchymal phenotypes.","evidence":"Co-IP, in vitro SUMOylation and ubiquitination assays, K129 mutagenesis, overexpression/knockdown with EMT marker readouts","pmids":["33791162"],"confidence":"Medium","gaps":["Mechanism by which SUMOylation blocks ubiquitination not resolved","In vivo relevance to EMT/tumor progression not tested"]},{"year":2023,"claim":"Demonstrated a non-catalytic, TDP2-independent role in TOP2 stability and etoposide survival, mapping the TOP2 interaction to residues 1-168 and showing additive sensitivity in ZATT/TDP2 double knockouts.","evidence":"Genome-wide CRISPR screens, deletion-mutant Co-IP, CHX-chase stability assays, double-KO epistasis","pmids":["37047518"],"confidence":"Medium","gaps":["Molecular basis of ZATT-mediated TOP2 stabilization unknown","Whether stabilization is SUMO-dependent not established"]},{"year":2023,"claim":"Revealed a chromatin co-regulator function in which ZNF451 partners with SLUG to recruit PCAF to the CCL5 promoter, coupling the protein to tumor-immune microenvironment signaling.","evidence":"Co-IP, ChIP, luciferase reporters, peptide competition, macrophage migration/activation assays","pmids":["37342906"],"confidence":"Medium","gaps":["Role of SUMO ligase activity in this transcriptional function untested","Generality beyond the CCL5 locus unknown"]},{"year":2025,"claim":"Connected ZNF451 to double-strand break signaling by showing it SUMOylates and stabilizes RNF168, amplifying H2A/H2AX ubiquitination, and that it co-regulates RNF168 with RNF8 in a competitive-cooperative manner.","evidence":"Co-IP, in-cell SUMOylation assays, IF at damage sites, KO/KD epistasis of ZNF451/RNF8/RNF168, ubiquitination assays","pmids":["40055579"],"confidence":"Medium","gaps":["Structural basis of mutual ZNF451/RNF8 inhibition not defined","RNF168 SUMO acceptor sites not mapped"]},{"year":2024,"claim":"Implicated ZNF451 in tissue protection in vivo, showing its downregulation drives fibroblast activation via PDGFB/PI3K-Akt and that knockout worsens while overexpression protects against pulmonary fibrosis.","evidence":"ZNF451 knockout mice, lentiviral overexpression rescue, RNA-seq, migration assays, immunoblot","pmids":["38600524"],"confidence":"Medium","gaps":["Whether the fibrosis phenotype depends on SUMO ligase activity unknown","Direct molecular target linking ZNF451 to PDGFB not identified"]},{"year":2024,"claim":"Proposed a topological transcriptional role in which ZATT inhibits TOP2B catalytic activity during estrogen signaling to shape chromatin contacts.","evidence":"ChIP, topoisomerase activity assays, KO/KD epistasis, 3D genome contact analysis, transcriptional assays (preprint)","pmids":["38328138"],"confidence":"Low","gaps":["Preprint, not peer reviewed","Mechanism of supercoiling accumulation inferred, not directly measured","Requirement for ZATT catalytic activity vs scaffolding not separated"]},{"year":null,"claim":"How ZNF451's diverse substrate targeting is selected and regulated — and which of its many roles depend on SUMO ligase activity versus non-catalytic scaffolding — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model for substrate selection across DNA repair, transcription, and EMT","Catalytic vs scaffolding requirements not systematically dissected","Upstream signals that recruit ZNF451 to specific complexes unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,3,4,5,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,4,5,8]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,6]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[1,4]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[1,7,8]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[4]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,5]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,6]}],"complexes":["PML nuclear body"],"partners":["TOP2A","TDP2","PML","RNF168","TWIST2","SLUG","UBE2I","RNF8"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y4E5","full_name":"E3 SUMO-protein ligase ZNF451","aliases":["Coactivator for steroid receptors","E3 SUMO-protein transferase ZNF451","Zinc finger protein 451"],"length_aa":1061,"mass_kda":121.5,"function":"E3 SUMO-protein ligase; has a preference for SUMO2 and SUMO3 and facilitates UBE2I/UBC9-mediated sumoylation of target proteins (PubMed:26524493, PubMed:26524494). Plays a role in protein SUMO2 modification in response to stress caused by DNA damage and by proteasome inhibitors (in vitro). Required for MCM4 sumoylation (By similarity). Has no activity with SUMO1 (PubMed:26524493). Preferentially transfers an additional SUMO2 chain onto the SUMO2 consensus site 'Lys-11' (PubMed:26524493). Negatively regulates transcriptional activation mediated by the SMAD4 complex in response to TGF-beta signaling. Inhibits EP300-mediated acetylation of histone H3 at 'Lys-9' (PubMed:24324267). Plays a role in regulating the transcription of AR targets (PubMed:18656483)","subcellular_location":"Nucleus; Nucleus, PML body; Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y4E5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF451","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZNF451","total_profiled":1310},"omim":[{"mim_id":"615708","title":"ZINC FINGER PROTEIN 451; ZNF451","url":"https://www.omim.org/entry/615708"},{"mim_id":"605764","title":"TYROSYL-DNA PHOSPHODIESTERASE 2; TDP2","url":"https://www.omim.org/entry/605764"},{"mim_id":"126430","title":"TOPOISOMERASE, DNA, II, ALPHA; TOP2A","url":"https://www.omim.org/entry/126430"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":66.3}],"url":"https://www.proteinatlas.org/search/ZNF451"},"hgnc":{"alias_symbol":["KIAA0576","COASTER","dJ417I1.1","KIAA1702","ZATT"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y4E5","domains":[{"cath_id":"-","chopping":"201-313_349-410","consensus_level":"high","plddt":82.7614,"start":201,"end":410},{"cath_id":"-","chopping":"471-566","consensus_level":"medium","plddt":78.5864,"start":471,"end":566},{"cath_id":"-","chopping":"605-699","consensus_level":"medium","plddt":83.1773,"start":605,"end":699},{"cath_id":"-","chopping":"733-773_787-811","consensus_level":"high","plddt":84.523,"start":733,"end":811},{"cath_id":"3.40.50,3.40.50","chopping":"880-1022","consensus_level":"high","plddt":83.1656,"start":880,"end":1022}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y4E5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y4E5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y4E5-F1-predicted_aligned_error_v6.png","plddt_mean":68.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF451","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF451"},"sequence":{"accession":"Q9Y4E5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y4E5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y4E5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y4E5"}},"corpus_meta":[{"pmid":"15840442","id":"PMC_15840442","title":"A roller coaster ride with the mitotic cyclins.","date":"2005","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15840442","citation_count":148,"is_preprint":false},{"pmid":"28912134","id":"PMC_28912134","title":"ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28912134","citation_count":126,"is_preprint":false},{"pmid":"26524494","id":"PMC_26524494","title":"Structural basis for catalytic activation by the human ZNF451 SUMO E3 ligase.","date":"2015","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26524494","citation_count":117,"is_preprint":false},{"pmid":"33296677","id":"PMC_33296677","title":"The ZATT-TOP2A-PICH Axis Drives Extensive Replication Fork Reversal to Promote Genome Stability.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33296677","citation_count":67,"is_preprint":false},{"pmid":"20091125","id":"PMC_20091125","title":"The complete mitochondrial genome of the yellow coaster, Acraea issoria (Lepidoptera: Nymphalidae: Heliconiinae: Acraeini): sequence, gene organization and a unique tRNA translocation event.","date":"2009","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20091125","citation_count":66,"is_preprint":false},{"pmid":"21224413","id":"PMC_21224413","title":"Roller Coaster Scanning reveals spontaneous triggering of dendritic spikes in CA1 interneurons.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21224413","citation_count":59,"is_preprint":false},{"pmid":"18656483","id":"PMC_18656483","title":"ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18656483","citation_count":50,"is_preprint":false},{"pmid":"27343429","id":"PMC_27343429","title":"The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27343429","citation_count":30,"is_preprint":false},{"pmid":"25735770","id":"PMC_25735770","title":"Alternative splicing and co-option of transposable elements: the case of TMPO/LAP2α and ZNF451 in mammals.","date":"2015","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25735770","citation_count":30,"is_preprint":false},{"pmid":"33791162","id":"PMC_33791162","title":"ZNF451 stabilizes TWIST2 through SUMOylation and promotes epithelial-mesenchymal transition.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33791162","citation_count":22,"is_preprint":false},{"pmid":"29160298","id":"PMC_29160298","title":"TDP2, TOP2, and SUMO: what is ZATT about?","date":"2017","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29160298","citation_count":20,"is_preprint":false},{"pmid":"28298437","id":"PMC_28298437","title":"Riding the metalloproteinase roller coaster.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28298437","citation_count":20,"is_preprint":false},{"pmid":"37342906","id":"PMC_37342906","title":"ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37342906","citation_count":19,"is_preprint":false},{"pmid":"35590466","id":"PMC_35590466","title":"COVID-19 and erythrocrine function: The roller coaster and danger.","date":"2022","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35590466","citation_count":17,"is_preprint":false},{"pmid":"32841734","id":"PMC_32841734","title":"Identification of Annexin A2 as a key mTOR target to induce roller coaster pattern of autophagy fluctuation in stress.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32841734","citation_count":13,"is_preprint":false},{"pmid":"40055579","id":"PMC_40055579","title":"ZNF451 collaborates with RNF8 to regulate RNF168 localization and amplify ubiquitination signaling to promote DNA damage repair and regulate radiosensitivity.","date":"2025","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/40055579","citation_count":11,"is_preprint":false},{"pmid":"29532883","id":"PMC_29532883","title":"LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29532883","citation_count":8,"is_preprint":false},{"pmid":"39534688","id":"PMC_39534688","title":"Single-Cell Spatial-Temporal Analysis of ZNF451 in Mediating Drug Resistance and CD8+ T Cell Dysfunction.","date":"2024","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/39534688","citation_count":6,"is_preprint":false},{"pmid":"37047518","id":"PMC_37047518","title":"Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37047518","citation_count":5,"is_preprint":false},{"pmid":"21636971","id":"PMC_21636971","title":"There is more to autophagy than induction: regulating the roller coaster.","date":"2011","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/21636971","citation_count":4,"is_preprint":false},{"pmid":"38600524","id":"PMC_38600524","title":"Loss of ZNF451 mediates fibroblast activation and promotes lung fibrosis.","date":"2024","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/38600524","citation_count":2,"is_preprint":false},{"pmid":"38328138","id":"PMC_38328138","title":"Topological regulation of the estrogen transcriptional response by ZATT-mediated inhibition of TOP2B activity.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38328138","citation_count":2,"is_preprint":false},{"pmid":"38002004","id":"PMC_38002004","title":"From Living in Saltwater to a Scarcity of Salt and Water, and Then an Overabundance of Salt-The Biological Roller Coaster to Which the Renin-Angiotensin System Has Had to Adapt: An Editorial.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/38002004","citation_count":2,"is_preprint":false},{"pmid":"40768093","id":"PMC_40768093","title":"Corona VRus Coaster: the virtual reality roller coaster of the proteins of SARS-CoV-2.","date":"2025","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/40768093","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12249,"output_tokens":3307,"usd":0.043176,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10822,"output_tokens":4139,"usd":0.078793,"stage2_stop_reason":"end_turn"},"total_usd":0.121969,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"The N-terminal domain of ZNF451 constitutes the catalytic module for SUMO E3 ligase activity, containing tandem SUMO-interaction motifs (SIMs) bridged by a Pro-Leu-Arg-Pro (PLRP) motif. The first SIM and PLRP motif engage thioester-charged E2~SUMO while the second SIM binds a second SUMO molecule on the back side of E2, stabilizing the closed configuration for nucleophilic attack. ZNF451 is SUMO2-specific, and SUMO modification of ZNF451 itself may contribute to activity by providing a second SUMO molecule interacting with E2.\",\n      \"method\": \"Crystal structure determination combined with biochemical assays and mutagenesis of the catalytic module\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro biochemical reconstitution plus mutagenesis in a single rigorous study\",\n      \"pmids\": [\"26524494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZATT (ZNF451) is a multifunctional DNA repair factor that resolves topoisomerase 2 DNA-protein cross-links (TOP2cc) via two mechanisms: (1) ZATT binding to TOP2cc facilitates proteasome-independent TDP2 hydrolase activity on stalled TOP2cc, and (2) ZATT SUMO ligase activity promotes TDP2 interactions with SUMOylated TOP2 through a 'split-SIM' SUMO2 engagement platform, enabling efficient TDP2 recruitment.\",\n      \"method\": \"Biochemical reconstitution assays, Co-IP/pulldown, in vitro TDP2 hydrolase activity assays, cell-based DNA repair assays, mutagenesis\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including in vitro reconstitution, activity assays, mutagenesis, and cellular validation in a single study\",\n      \"pmids\": [\"28912134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZNF451 localizes to PML bodies in the nucleus, interacts with SUMO E2 conjugase Ubc9 and SUMOs, and is itself covalently SUMOylated at multiple non-consensus sites. Its noncovalent SUMO-binding activity (SIM) is required for its own sumoylation. SUMO modification regulates ZNF451 nuclear compartmentalization: co-expression with SENP1 or SENP2 redistributes ZNF451 from nuclear domains to speckles/nucleoplasm. ZNF451 interacts with PIAS1 (which does not act as an E3 for ZNF451) resulting in disintegration of ZNF451 nuclear domains. ZNF451 interacts weakly with androgen receptor (AR) in a SUMO-1-enhanced manner. Ablation of endogenous ZNF451 in prostate cancer cells significantly decreases expression of AR target genes.\",\n      \"method\": \"Co-IP, immunofluorescence/localization, sumoylation assays, siRNA knockdown, reporter assays, SENP co-expression experiments\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple orthogonal methods (Co-IP, localization, knockdown with gene expression readout) in a single lab\",\n      \"pmids\": [\"18656483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF451 isoform 1 (ZNF451-1) functions as a SUMO2/3-specific E3 ligase for PML and selected PML body components in vitro, using the same biochemical mechanism as SUMO chain formation. In vivo, RNAi depletion of ZNF451-1 leads to PML stabilization and an increased number of PML bodies, while PML degradation upon arsenic trioxide treatment is not ZNF451-1 dependent. ZNF451-1 cooperates with RNF4 to regulate physiological PML levels.\",\n      \"method\": \"In vitro SUMO E3 ligase assays, mutational analysis, RNAi knockdown with immunofluorescence and western blot readouts\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution plus cellular KD with specific phenotypic readout, single lab\",\n      \"pmids\": [\"27343429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Upon replication stress, TOP2A SUMOylation is mediated by the SUMO E3 ligase ZATT (ZNF451), which promotes recruitment of the SUMO-targeted DNA translocase PICH to stalled forks. Disruption of the ZATT-TOP2A-PICH axis results in accumulation of partially reversed forks and enhanced genome instability, placing ZATT in a sequential two-step fork reversal pathway downstream of HLTF/ZRANB3/SMARCAL1.\",\n      \"method\": \"Co-IP, SUMO modification assays, replication fork analysis (electron microscopy/fiber assays), genetic epistasis using knockout/knockdown cell lines, immunofluorescence\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, multiple KO/KD genetic epistasis experiments, replication fork phenotype readout with multiple orthogonal methods\",\n      \"pmids\": [\"33296677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZNF451 directly binds to and SUMOylates TWIST2 at lysine 129, blocking ubiquitination and proteasome-dependent degradation of TWIST2. Ectopic expression of ZNF451 increases TWIST2 protein levels in mammary epithelial cells and increases expression of mesenchymal markers, while depletion of ZNF451 suppresses mesenchymal phenotypes.\",\n      \"method\": \"Co-IP, in vitro SUMOylation assay, ubiquitination assay, site-directed mutagenesis (K129 site), overexpression/knockdown with immunoblot and EMT marker readouts\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, mutagenesis of SUMOylation site, and functional cellular assays in single lab\",\n      \"pmids\": [\"33791162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF451 interacts with the transcriptional activator SLUG and the complex preferentially recruits the acetyltransferase PCAF to the CCL5 promoter, enhancing acetylation of SLUG and local chromatin to selectively facilitate CCL5 transcription. This promotes recruitment and activation of tumor-associated macrophages.\",\n      \"method\": \"Co-IP, ChIP, luciferase reporter assays, peptide competition experiments, macrophage migration/activation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP, ChIP, and functional cellular assays in single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37342906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZATT (ZNF451) has a TDP2-independent role in promoting cell survival after etoposide treatment. The N-terminal 1-168 residues of ZATT are required for interaction with TOP2 and this interaction is critical for etoposide sensitivity. Depletion of ZATT accelerates TOP2 degradation after etoposide or cycloheximide treatment, suggesting ZATT promotes TOP2 stability and participates in TOP2 turnover. ZATT/TDP2 double knockout shows additive hypersensitivity to etoposide, confirming independent pathways.\",\n      \"method\": \"Genome-wide CRISPR screens, deletion mutant analysis, Co-IP, TOP2 stability assays (CHX chase), double KO epistasis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen plus deletion mutant Co-IP plus genetic epistasis (DKO), single lab\",\n      \"pmids\": [\"37047518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF451 catalyzes SUMO2 modification of RNF168 at DNA damage sites, stabilizing RNF168 and enhancing its accumulation at damage sites, which increases ubiquitination of downstream histone H2A/H2AX and promotes DSB repair. ZNF451 and RNF8 jointly regulate RNF168 in a competitive and cooperative manner: the interaction of RNF168 with either ZNF451 or RNF8 mutually inhibits each other, yet simultaneous loss of both markedly impedes RNF168 recruitment to damage sites.\",\n      \"method\": \"Co-IP, SUMOylation assays, immunofluorescence at damage sites, genetic epistasis (KO/KD of ZNF451, RNF8, RNF168), H2A/H2AX ubiquitination assays, irradiation experiments\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, in-cell SUMOylation assays, and genetic epistasis, single lab\",\n      \"pmids\": [\"40055579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZATT (ZNF451) inhibits TOP2B catalytic activity in response to estrogen stimulation, contributing to topological regulation of the estrogen transcriptional response. This inhibition requires estrogen receptor α (ERα), a non-catalytic function of TOP2A, and ZATT SUMO ligase activity, stabilizing regulatory chromatin contacts likely through local accumulation of DNA supercoiling.\",\n      \"method\": \"ChIP, topoisomerase activity assays, genetic epistasis (KO/KD of ZATT, TOP2A, TOP2B), 3D genome contact analysis, transcriptional assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — preprint, single lab, multiple methods but not yet peer reviewed\",\n      \"pmids\": [\"38328138\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF451 downregulation in pulmonary fibrosis triggers fibroblast activation by increasing expression of PDGFB and subsequently activating PI3K/Akt signaling. ZNF451 knockout mice develop more severe pulmonary fibrosis, while ZNF451 overexpression protects mice from bleomycin-induced fibrosis.\",\n      \"method\": \"ZNF451 knockout mice, lentiviral overexpression, RNA-seq, migration assays, immunofluorescence, immunoblot\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO mouse model plus overexpression rescue plus pathway identification by RNA-seq, single lab\",\n      \"pmids\": [\"38600524\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF451 (ZATT) is a SUMO2/3-specific E3 ligase whose N-terminal tandem-SIM/PLRP catalytic module stabilizes the E2~SUMO thioester for transfer; it SUMOylates multiple substrates—including TOP2, TOP2A (promoting fork reversal via PICH recruitment), PML, RNF168 (stabilizing it for H2A/H2AX ubiquitination in DSB repair), and TWIST2 (blocking its proteasomal degradation to drive EMT)—and directly facilitates TDP2-mediated hydrolytic resolution of trapped TOP2 cleavage complexes through a 'split-SIM' SUMO2 engagement platform, while also acting as a transcriptional co-regulator at PML bodies that modulates androgen receptor target gene expression and, in the context of estrogen signaling, inhibits TOP2B catalytic activity to shape chromatin topology.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF451 (ZATT) is a SUMO2/3-specific E3 ligase that operates at the interface of SUMO conjugation, genome maintenance, and transcriptional control [#0, #1]. Its catalytic activity resides in an N-terminal module of tandem SUMO-interaction motifs bridged by a Pro-Leu-Arg-Pro (PLRP) element: the first SIM and PLRP engage thioester-charged E2~SUMO while the second SIM binds a second SUMO on the back face of the E2, stabilizing the closed conformation that drives transfer [#0]. Through this chemistry ZNF451 modifies multiple substrates and assembles SUMO-based recognition platforms. In DNA repair, it resolves trapped topoisomerase-2 DNA-protein cross-links both by directly facilitating proteasome-independent TDP2 hydrolase activity and by SUMOylating TOP2 to create a 'split-SIM' SUMO2 platform for TDP2 recruitment [#1]; under replication stress it SUMOylates TOP2A to recruit the translocase PICH and drive fork reversal [#4]; and it SUMOylates RNF168 at damage sites to stabilize it and amplify downstream H2A/H2AX ubiquitination during double-strand break repair [#8]. ZNF451 localizes to PML nuclear bodies, where it acts as a SUMO2/3 E3 for PML and cooperates with RNF4 to set physiological PML levels [#2, #3]. Beyond genome maintenance it stabilizes substrates such as TWIST2 by blocking its ubiquitin-dependent degradation to promote mesenchymal phenotypes [#5] and serves as a transcriptional co-regulator, supporting androgen-receptor target gene expression and partnering with SLUG to recruit PCAF and selectively activate CCL5 [#2, #6]. In vivo, ZNF451 loss exacerbates bleomycin-induced pulmonary fibrosis through PDGFB/PI3K-Akt-driven fibroblast activation [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established ZNF451 as a SUMO-pathway protein by showing it localizes to PML bodies, binds Ubc9 and SUMO, is itself SUMOylated, and influences androgen-receptor target gene expression — the first functional placement of the protein.\",\n      \"evidence\": \"Co-IP, immunofluorescence, sumoylation and reporter assays, siRNA knockdown in prostate cancer cells\",\n      \"pmids\": [\"18656483\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define catalytic E3 activity or mechanism\", \"SUMO sites mapped only as non-consensus, not residue-resolved\", \"AR co-regulation correlative, no direct enzymatic link\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the catalytic mechanism, showing ZNF451's N-terminal tandem-SIM/PLRP module stabilizes the E2~SUMO closed configuration and confers SUMO2 specificity, defining it as a bona fide SUMO E3 ligase.\",\n      \"evidence\": \"Crystal structure with in vitro biochemistry and mutagenesis of the catalytic module\",\n      \"pmids\": [\"26524494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrate repertoire not addressed structurally\", \"Contribution of ZNF451 auto-SUMOylation to activity inferred, not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified PML and PML body components as cellular SUMO2/3 substrates of ZNF451 and placed it alongside RNF4 in regulating PML homeostasis.\",\n      \"evidence\": \"In vitro SUMO E3 ligase assays, mutational analysis, RNAi knockdown with IF/WB readouts\",\n      \"pmids\": [\"27343429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Arsenic-induced PML degradation shown ZNF451-independent, leaving trigger specificity open\", \"Direct vs indirect cooperation with RNF4 not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined ZATT/ZNF451 as a topoisomerase-2 cleavage-complex repair factor that both potentiates TDP2 hydrolase activity directly and builds a split-SIM SUMO2 platform to recruit TDP2 to SUMOylated TOP2.\",\n      \"evidence\": \"Biochemical reconstitution, Co-IP, in vitro TDP2 activity assays, cell-based repair assays, mutagenesis\",\n      \"pmids\": [\"28912134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo weight of catalytic vs non-catalytic resolution unresolved\", \"Substrate specificity across TOP2 isoforms not delineated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended ZATT into replication-stress responses, showing TOP2A SUMOylation recruits PICH to drive a defined step of fork reversal, linking SUMO ligase activity to genome stability at stalled forks.\",\n      \"evidence\": \"Co-IP, SUMO modification assays, replication fork EM/fiber analysis, genetic epistasis in KO/KD lines\",\n      \"pmids\": [\"33296677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger for ZATT engagement at forks not defined\", \"Interplay with the upstream HLTF/ZRANB3/SMARCAL1 step mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Broadened the substrate scope beyond genome maintenance by showing ZNF451 SUMOylates TWIST2 at K129 to block its degradation and promote mesenchymal phenotypes.\",\n      \"evidence\": \"Co-IP, in vitro SUMOylation and ubiquitination assays, K129 mutagenesis, overexpression/knockdown with EMT marker readouts\",\n      \"pmids\": [\"33791162\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which SUMOylation blocks ubiquitination not resolved\", \"In vivo relevance to EMT/tumor progression not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated a non-catalytic, TDP2-independent role in TOP2 stability and etoposide survival, mapping the TOP2 interaction to residues 1-168 and showing additive sensitivity in ZATT/TDP2 double knockouts.\",\n      \"evidence\": \"Genome-wide CRISPR screens, deletion-mutant Co-IP, CHX-chase stability assays, double-KO epistasis\",\n      \"pmids\": [\"37047518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of ZATT-mediated TOP2 stabilization unknown\", \"Whether stabilization is SUMO-dependent not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a chromatin co-regulator function in which ZNF451 partners with SLUG to recruit PCAF to the CCL5 promoter, coupling the protein to tumor-immune microenvironment signaling.\",\n      \"evidence\": \"Co-IP, ChIP, luciferase reporters, peptide competition, macrophage migration/activation assays\",\n      \"pmids\": [\"37342906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Role of SUMO ligase activity in this transcriptional function untested\", \"Generality beyond the CCL5 locus unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected ZNF451 to double-strand break signaling by showing it SUMOylates and stabilizes RNF168, amplifying H2A/H2AX ubiquitination, and that it co-regulates RNF168 with RNF8 in a competitive-cooperative manner.\",\n      \"evidence\": \"Co-IP, in-cell SUMOylation assays, IF at damage sites, KO/KD epistasis of ZNF451/RNF8/RNF168, ubiquitination assays\",\n      \"pmids\": [\"40055579\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of mutual ZNF451/RNF8 inhibition not defined\", \"RNF168 SUMO acceptor sites not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Implicated ZNF451 in tissue protection in vivo, showing its downregulation drives fibroblast activation via PDGFB/PI3K-Akt and that knockout worsens while overexpression protects against pulmonary fibrosis.\",\n      \"evidence\": \"ZNF451 knockout mice, lentiviral overexpression rescue, RNA-seq, migration assays, immunoblot\",\n      \"pmids\": [\"38600524\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the fibrosis phenotype depends on SUMO ligase activity unknown\", \"Direct molecular target linking ZNF451 to PDGFB not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proposed a topological transcriptional role in which ZATT inhibits TOP2B catalytic activity during estrogen signaling to shape chromatin contacts.\",\n      \"evidence\": \"ChIP, topoisomerase activity assays, KO/KD epistasis, 3D genome contact analysis, transcriptional assays (preprint)\",\n      \"pmids\": [\"38328138\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Preprint, not peer reviewed\", \"Mechanism of supercoiling accumulation inferred, not directly measured\", \"Requirement for ZATT catalytic activity vs scaffolding not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZNF451's diverse substrate targeting is selected and regulated — and which of its many roles depend on SUMO ligase activity versus non-catalytic scaffolding — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model for substrate selection across DNA repair, transcription, and EMT\", \"Catalytic vs scaffolding requirements not systematically dissected\", \"Upstream signals that recruit ZNF451 to specific complexes unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 4, 5, 8]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0016605\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [1, 7, 8]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 6]}\n    ],\n    \"complexes\": [\"PML nuclear body\"],\n    \"partners\": [\"TOP2A\", \"TDP2\", \"PML\", \"RNF168\", \"TWIST2\", \"SLUG\", \"UBE2I\", \"RNF8\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}